RECRUITING

A Bundled Intervention

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Opioid overdose deaths have reached historically high records in the United States and are particularly concentrated among patients after emergency department (ED) discharge. Evidence-based treatment modules to reduce repeat opioid overdose and mortality are lacking in this patient population. A bundled intervention is proposed, including telehealth, peer support specialist, buprenorphine, and linkage for definitive care, that is designed to increase treatment uptake in this patient population post-ED discharge, reduce repeat opioid overdoses, and end overdose deaths.

Official Title

A Bundled Intervention to End Opioid Overdose by Increasing Treatment Uptake Post Emergency Department Discharge

Quick Facts

Study Start:2025-02-13
Study Completion:2030-11-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06593093

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:19 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. 19 years or older (the age of majority in Alabama);
  2. 2. diagnosis of OUD and experiencing opioid overdose in the last 12 months;
  3. 3. prescribed buprenorphine in the ED and willing to continue buprenorphine post-ED discharge;
  4. 4. English speaking;
  5. 5. not actively psychotic and suicidal, or cognitively impaired.
  6. 6. Patients who are admitted to the hospital from the ED will be eligible for enrollment.
  1. 1. living in a restricted environment (e.g., prison or jail facility, etc.);
  2. 2. currently enrolled in other clinical studies;
  3. 3. anticipated to take other prescribed opioids except buprenorphine for a medical condition longer than three months;
  4. 4. known allergic reaction to buprenorphine;
  5. 5. critically ill or injured;
  6. 6. females with pregnancy (they are anticipated to request a higher level of care).

Contacts and Locations

Study Contact

Li Li, MD;PhD
CONTACT
2059346269
liyli@uabmc.edu

Principal Investigator

Li Li, MD;PhD
PRINCIPAL_INVESTIGATOR
University of Alabama at Birmingham

Study Locations (Sites)

UAB
Birmingham, Alabama, 35294
United States

Collaborators and Investigators

Sponsor: University of Alabama at Birmingham

  • Li Li, MD;PhD, PRINCIPAL_INVESTIGATOR, University of Alabama at Birmingham

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-02-13
Study Completion Date2030-11-30

Study Record Updates

Study Start Date2025-02-13
Study Completion Date2030-11-30

Terms related to this study

Keywords Provided by Researchers

  • Emergency department
  • post discharge
  • buprenorphine

Additional Relevant MeSH Terms

  • Opioid Use Disorder
  • Opioid Overdose